


IN THE CLAIMS:

Please cancel claims 2, 4, 5, and 6 from the present application without disclaimer or prejudice.

Please amend claims 1, 3, 7, 8, 9, 11, and 12 as follows:

Claim 1:

1. A compound of the Formula I



wherein:


R¹ is selected from H; -C₁₋₄alkyl; -CO-C₁₋₄alkyl; -CO-O-C₁₋₄alkyl; -CO-O-C₂₋₄alkenyl; -C₁₋₄alkylene-CO NR⁴ R⁵ (wherein R⁴ and R⁵ are independently selected from H and C₁₋₄alkyl); -C₁₋₄alkylene-COOR⁶ (wherein R⁶ is selected from H and C₁₋₄alkyl); -C₁₋₃alkylene-Ph and -CO-O(CH₂)_nPh wherein the phenyl groups in -C₁₋₃alkylene-Ph and -CO-O(CH₂)_nPh are optionally substituted by R^a and/or R^b and R^a and R^b are independently selected from C₁₋₄alkyl, halogen, hydroxy, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkanoylamino, nitro, cyano, carboxy, carbamoyl, C₁₋₄alkoxycarbonyl, thiol, C₁₋₄alkylsulfanyl, C₁₋₄alkylsulfinyl, C₁₋₄alkylsulfonyl and sulfonamido; and n=0-4;

R² is selected from H; -C₁₋₄alkyl; -CO-C₁₋₄alkyl; and -COOC₁₋₄alkyl; and -C₁₋₃alkylene-Ph optionally substituted on the phenyl ring by R^a and/or R^b;

R³ is selected from H; OH; CN; CF₃; NO₂; -C₁₋₄alkyl; -C₁₋₄alkylene-R⁷; -C₂₋₄alkenylene-R⁷; -C₂₋₄alkynylene-R⁷; R⁷; OR⁷ (where R⁷ is selected from phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5

B2

heteroatoms selected from O, N and S and any aryl ring in R⁷ is optionally substituted by R^a and/or R^b); C₂₋₄alkenyl; halogen; -(CH₂)_nCOOR⁸ (where n = 0-3 and R⁸ represents H, C₁₋₄alkyl, or C₂₋₄alkenyl); -CONR⁹R¹⁰ (where R⁹ and R¹⁰ independently represent H, C₁₋₄alkyl, C₂₋₄alkenyl, -O-C₁₋₄alkyl, -O-C₂₋₄alkenyl or -C₁₋₃alkylenePh (wherein Ph is optionally substituted by R^a and R^b as hereinabove defined); -CON(R¹¹)OR¹² (where R¹¹ and R¹² independently represent H, C₁₋₄alkyl or C₂₋₄alkenyl); -CONR¹³-CR^{13a}R¹⁴-COOR¹⁷, (where R¹³ and R^{13a} are independently H or C₁₋₄alkyl, R¹⁷ is H or C₁₋₆alkyl, R¹⁴ is selected from the side chain of a lipophilic amino acid, carbamoylC₁₋₄alkyl, N-(monoC₁₋₄alkyl)carbamoylC₁₋₄alkyl and N-(diC₁₋₄alkyl)carbamoylC₁₋₄alkyl) having L or D configuration at the chiral alpha carbon in the corresponding free amino acid; a lactone of formula:




C₁₋₄alkyl monosubstituted on carbon with =N-OH;

a group of Formula -X-R¹⁵ (where X is selected from O, CO, CH₂, S, SO, SO₂ and R¹⁵ is selected from C₁₋₆alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms selected from O, N and S and any aryl ring in R¹⁵ is optionally substituted by R^a and/or R^b;

p is 0-3 in which R³ values can be the same or different;

L is a linking moiety selected from the following groups written from left to right in Formula I:

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000



(wherein the piperazine and perhydro-1,4-diazepine rings are optionally substituted);

~~-CO-NR¹⁶; -CH₂-NR¹⁶-; -CH₂S-; -CH₂O-; -CH₂-CHR¹⁶; -CH=CR¹⁶-; -CH₂NR¹⁶-T-;~~

~~-CH₂NR¹⁶-SO₂-; -CH₂-NR¹⁶-CO-T¹-; -CO-NR¹⁶-T-; -CH₂S-T-; -CH₂O-T- (where R¹⁶ is selected from H, C₁₋₄alkyl, C₁₋₄alkylene-Z, -CO-C₁₋₄alkylene-Z, -CO-C₁₋₆alkyl, -COZ, Z and Z is selected from -O-C₁₋₄alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms selected from O, N and S and any aryl ring in R¹⁶ is optionally substituted by R^a and/or R^b as hereinabove defined; where, T represents -(CH₂)^m- where m is 1-4 and T is optionally monosubstituted with any value of R¹⁶ other than H; and~~

~~where T¹ represents -(CH₂)^m- wherein m¹ is 0-4 and T is optionally monosubstituted with any value of R¹⁶ other than H);~~

A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms where the heteroatoms are independently selected from O, N & S;

or a -S-S- dimer thereof when R²=H; or a N-oxide thereof;

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

B2

Claim 3:

3. A compound according to claim 1 wherein A is phenyl or naphthyl.

B2


Claim 7:

7. A compound of the formula A:

LAW OFFICES
FINNEGAN HENDERSON,
FARABOW GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4600

P *C22*

B 4
C 22
cont



A

wherein:

X is O or H₂;

n is 0 or 1;

t is 1 to 4;

R^{2'}, R^{3'}, R^{4'}, and R^{5'} are independently selected from: H; C₁-8alkyl, alkenyl, alkynyl, aryl, heterocycle, -CO-NR^{6'}R^{7'} or -CO-OR^{6'}, unsubstituted or substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with:
 - a. C₁-4alkyl,
 - b. (CH₂)_tOR^{6'},
 - c. (CH₂)_tNR^{6'}R^{7'},
 - d. halogen,
- 2) C₃-6cycloalkyl,
- 3) OR^{6'},
- 4) SR^{6'}, S(O)R^{6'}, SO₂R^{6'},
- 5) -NR^{6'}R^{7'},
- 6) -NR^{6'}-CO-R^{7'},
- 7) -NR^{6'}-CO-NR^{7'}R^{8'},

B 4

C 22
cont

- 8) $-\text{O}-\text{CO}-\text{NR}^{6'}\text{R}^{7'},$
- 9) $-\text{O}-\text{CO}-\text{OR}^{6'},$
- 10) $-\text{O}-\text{NR}^{6'}\text{R}^{7'},$
- 11) $-\text{SO}_2\text{NR}^{6'}\text{R}^{7'},$
- 12) $-\text{NR}^{6'}-\text{SO}_2-\text{R}^{7'},$
- 13) $-\text{CO}-\text{R}^{6'},$ or
- 14) $-\text{CO}-\text{OR}^{6'},$

and any two of $\text{R}^{2'}, \text{R}^{3'}, \text{R}^{4'},$ and $\text{R}^{5'}$ are optionally attached to the same carbon atom;
Y is aryl, heterocycle, unsubstituted or substituted with one or more of:

- 1) C1-4alkyl, unsubstituted or substituted with:
 - a. C1-4alkoxy,
 - b. $\text{NR}^{6'}\text{R}^{7'},$
 - c. C3-6cycloalkyl,
 - d. aryl or heterocycle,
 - e. HO,
- 2) aryl or heterocycle,
- 3) halogen,
- 4) $\text{OR}^{6'},$
- 5) $\text{NR}^{6'}\text{R}^{7'},$
- 6) CN
- 7) $\text{NO}_2,$ or
- 8) $\text{CF}_3;$

$\text{R}^{6'}, \text{R}^{7'}$ and $\text{R}^{8'}$ are independently selected from: H; C1-4alkyl, C3-6cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with:

- a) C1-4alkoxy,

43
C22
cont

- b) aryl or heterocycle,
- c) halogen,
- d) HO,
- e) $-\text{CO-R}^{9'}$,
- f) $-\text{SO}_2\text{R}^{9'}$, wherein

$\text{R}^{6'}$ and $\text{R}^{7'}$ may be joined in a ring, and

$\text{R}^{7'}$ and $\text{R}^{8'}$ may be joined in a ring;

$\text{R}^{9'}$ is C1-4alkyl or aralkyl;

a pharmaceutically acceptable salt thereof.

Claim 8:

8. A compound according to claim 1 which is any one of the following individual compounds or a pharmaceutically acceptable salt thereof:

(2S)-2-{2-benzyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-{2-benzyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid;

(2S)-2-({2-phenyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-phenylcarbonyl}-amino)-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-({2-phenyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-phenylcarbonyl}-amino)-4-methylsulfanylbutyric acid;

(2S)-2-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethyl]amino]-naphthalene-1-carbonyl}-amino)-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-({3-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethyl]amino}-naphthalene-1-carbonyl}-amino)-4-methylsulfanylbutyric acid;

(2S)-2-({3-phenyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-phenylcarbonyl}-amino)-4-methylsulfanylbutyric acid methyl ester;

4
22
Cont

(2S)-2-({3-phenyl-5[(cis)-3-sulfanylpyrrolidin-2-ylmethylamino]-phenylcarbonyl}-amino)-4-methylsulfanylbutyric acid;

(cis)-2-[(N-(4-methoxybenzyl)- N-(naphthalen-1-ylmethylamino)-methyl]-pyrrolidine-3-thiol ;

N-(naphthalen-1-ylmethyl)-N-[(cis)-3-sulfanylpyrrolidin-2-ylmethyl]-pentanamide;

N-(naphthalen-1-ylmethyl)-N-[(cis)-3-sulfanylpyrrolidin-2-ylmethyl]-2-(pyridin-3-yl)-acetamide ;

N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-3-methyl-N-(2-naphthalen-1-yl-ethyl)butyramide ;

N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-N-(2-naphthalen-1-yl-ethyl)-2-pyridin-3-yl-acetamide ;

(cis)-2-{[(3-methoxypropyl)-(2-naphthalen-1-ylethyl)amino]methyl}- pyrrolidine-3-thiol;

N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-2-(4-methoxy-phenyl)-N-(2-naphthalen-2-yl-ethyl)-acetamide;

(cis)-2-{[(2-(4-methoxyphenyl)ethyl)-(2-naphthalen-1-ylethyl)amino] methyl}- pyrrolidine-3-thiol;

N-(2,2-diphenyl-ethyl)-N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-3-methyl-butyramide ;

N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-3,3-dimethyl-N-(2-naphthalen-2-yl-ethyl)-butyramide;

N-(2,2-diphenyl-ethyl)-N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-3,3-dimethyl-butyramide;

(2S)-2-{3-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-(3-methoxy-propyl)-amino]-benzoylamino}-4-methylsulfanyl-butyric acid ;

N-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl]-3,3-dimethyl-N-(2-naphthalen-1-yl-ethyl)-butyramide;

(2S)-4-carbamoyl-2-({2-phenyl-5-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl}-amino)-butyric acid;

(2S)-4-carbamoyl-2-({2-phenyl-5-[(cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl}-amino)-butyric acid methyl ester;

2-(3-pyridyl)-N-(2,2-diphenyl-ethyl)-N-[(cis)-3-sulfanylpyrrolidin-2-ylmethyl)- acetamide;

6-methoxy-1-oxido-N-(2,2-diphenyl-ethyl)-N-[(cis)-3-sulfanylpyrrolidin-2-ylmethyl]-pyridine-3-carboxamide;

B 4
C 22
Cont

N-(naphthyl-1-yl-ethyl)-N-[(*cis*)-3-sulfanylpyrrolidin-2-yl-methyl]-thiazole-5-carboxamide;
6-methoxy-1-oxido-N-(naphthyl-1-yl-ethyl)-N-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethyl]-pyridine-3-carboxamide;
(2S)-2-{2-benzyl-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-benzyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethyl]amino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-benzyl-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethyl]amino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-phenethyl-5-[(*trans*)-3-sulfanylpyrrolidin-2-ylmethylamino]benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{phenethyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-benzyl-5-[(*trans*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-(phenethyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-(4-methylphenylethynyl)-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid;
(2S)-2-{2-benzyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid isopropyl ester;
(2S)-2-{2-benzyl-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;
(2S)-2-{2-benzyl-4-[(*trans*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;
(2S)-2-{2-benzyl-5-[(*trans*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;
(2S)-2-{2-phenyl-5-[(*trans*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;
(2S)-2-{2-phenyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;

*B-4
C-22
cont*

(2S)-2-[2-benzyl-5-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino]-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-{2-(4-methylphenethyl)-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-{2-(4-methylphenylethynyl)-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-(2-methoxyethyl)-1-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethyl]-4-(naphth-1-oyl)piperazine;

(*cis*)-2-[N-*isovaleryl*-N-(2-(naphth-1-yl)ethyl)aminomethyl]-3-sulfanylpyrrolidine;

(*cis*)-2-[N-(3-pyridylacetyl)-N-(naphth-1-yl)ethyl)aminomethyl]-3-sulfanylpyrrolidine;

(*cis*)-2-[N-1-oxido-6-methoxypyridin-3-ylcarbonyl)-N-(naphth-1-yl)ethyl)aminomethyl]-3-sulfanylpyrrolidine;

(*cis*)-2-[N-thiazol-5-ylcarbonyl)-N-(naphth-1-yl)ethyl)aminomethyl]-3-sulfanylpyrrolidine;

(2S)-2-[2-(4-fluorophenethyl)-4-[(*cis*)-3-sulfanyl]-pyrrolidin-2-ylmethylamino]-4-methylsulfanylbutyric acid;

methyl (2S)-2-[2-(4-fluorophenethyl)-4-[(*cis*)-3-sulfanylpyrrolidin-2-ylmethylamino]-4-methylsulfanylbutyrate;

(2S)-2-[2-(4-fluorophenethyl)-4-((2R,3R)-3-sulfanyl-pyrrolidin-2-ylmethylamino)-5-methylsulfanylbutyric acid;

(2S)-2-{2-Benzyl-5-[(2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-benzoylamino}-4-methylsulfanylbutyric acid methyl ester ;

(2S)-2-{2-Benzyl-5-[(2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-benzoylamino}-4-methylsulfanylbutyric acid ;

(2S)-2-({2-phenyl-5-[(2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl)-amino)-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-({2-phenyl-5-[(2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl)-amino)-4-methylsulfanylbutyric acid;

(2S)-2-({3-[(2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-naphthalene-1-carbonyl)-amino)-4-methylsulfanylbutyric acid methyl ester ;

(2S)-2-({3-[(2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-naphthalene-1-carbonyl)-amino)-4-methylsulfanylbutyric acid ;

B4
7.22
Cont

(2S)-2-({-3-phenyl-5{[2R,3R]-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl}-amino)-4-methylsulfanylbutyric acid methyl ester;

(2S)-2-({-3-phenyl-5{[2R,3R]-3-sulfanylpyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl}-amino)-4-methylsulfanylbutyric acid;

(2R,3R)-2-[{N-(4-methoxybenzyl)- N-(naphthalen-1-ylmethyl)-amino}-methyl]-pyrrolidine-3-thiol ;

N-(naphthalen-1-ylmethyl)-N-([2R,3R]-3-sulfanylpyrrolidin-2-ylmethyl)-pentanamide;

N-(naphthalen-1-ylmethyl)-N-([2R,3R]-3-sulfanylpyrrolidin-2-ylmethyl)-2-(pyridin-3-yl)-acetamide ;

N-((2R,3R)-3-sulfanyl-pyrrolidin-2-ylmethyl)-3-methyl-N-(2-naphthalen-1-yl-ethyl)butyramide ;

N-([2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-N-(2-naphthalen-1-yl-ethyl)-2-pyridin-3-yl-acetamide ;

(2R,3R)-2-{{(3-Methoxypropyl)-(2-naphthalen-1-ylethyl)amino]methyl}- pyrrolidine-3-thiol;

N-([2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-2-(4-methoxy-phenyl)-N-(2-naphthalen-2-yl-ethyl)-acetamide ;

(2R,3R)-2-{{(2-(4-Methoxyphenyl)ethyl)-(2-naphthalen-1-ylethyl)amino] methyl}- pyrrolidine-3-thiol ;

N-(2,2-Diphenyl-ethyl)-N-([2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-3-methyl-butyramide ;

N-([2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-3,3-dimethyl-N-(2-naphthalen-2-yl-ethyl)-butyramide ;

N-(2,2-Diphenyl-ethyl)-N-([2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-3,3-dimethyl-butyramide ;

(2S)-2-{3-{{[2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-(3-methoxy-propyl)-amino]-benzoylamino}-4-methylsulfanyl-butyric acid ;

N-([2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-3,3-dimethyl-N-(2-naphthalen-1-yl-ethyl)-butyramide ;

(2S)-4-carbamoyl-2-{{2-phenyl-5{[2R,3R]-3-sulfanyl-pyrrolidin-2-ylmethyl)-amino]-phenylcarbonyl}-amino)-butyric acid;

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

B 4
C 22
cont

(2S)-4-carbamoyl-2-({2-phenyl-5-[(2R,3R)-3-sulfanyl-pyrrolidin-2-ylmethyl]-amino]-phenylcarbonyl}-amino)-butyric acid methyl ester;
2-(3-pyridyl)-N-(2,2-diphenyl-ethyl)-N-((2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-acetamide;
6-methoxy-1-oxido-N-(2,2-diphenyl-ethyl)-N-((2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-pyridine-3-carboxamide;
N-(naphthyl-1-yl-ethyl)-N-((2R,3R)-3-sulfanylpyrrolidin-2-yl-methyl)-thiazole-5-carboxamide;
6-methoxy-1-oxido-N-(naphthyl-1-yl-ethyl)-N-((2R,3R)-3-sulfanylpyrrolidin-2-ylmethyl)-pyridine-3-carboxamide;
(2S)-2-{2-benzyl-4-[(2R,3R)-3-sulfanyl-pyrrolidin-2-ylmethyl]-amino]-benzoylamino}-4-methylsulfanyl-butyric acid; and
(2S)-2-(2-methoxy-ethyl)-1-((2R,3R)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine.

Claim 9:

9. A pharmaceutical composition which comprises a compound according to any one of claims 1, 3, 7, or 8 and a pharmaceutically-acceptable carrier.

B 5
Claim 11:

11. A compound according to any one of claims 1, 3, 7 or 8 for use as a medicament.

Claim 12:

12. A compound according to any one of claims 1, 3, 7 or 8 for use in the preparation of a medicament for treatment of a disease mediated through farnesylation of mutant ras.

Please add claims 14-17 as follows: